Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 7.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.3K citations · Full text

Medicine, Oncology, Pharmacology +13

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

Bin‐Zhi Qian, Jiufeng Li, Hui Zhang et al. · Nature · 2011 · 2.9K citations · Full text

Medicine, Cancer Biology, Oncology +14

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Medicine, Oncology, Pharmacology +11

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

Tomi Akinyemiju, Semaw Ferede Abera, Muktar Beshir Ahmed et al. · JAMA Oncology · 2017 · 2K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16